Cofilin-1 Peptide Drug Enhances Cancer Cell Uptake
Summary
The USPTO published patent application US20260108640A1 for a cofilin-1 peptide composition designed to enhance cellular uptake in cancer cells. The peptide mimics endogenous cofilin-1 and incorporates transmembrane amino acid sequences to improve drug delivery, affecting cancer cell migration and invasion while enabling conjugation with chelators for diagnostic imaging. Filed October 22, 2024 under application number 18923581 by inventors Yi-Jang Lee, Min-Ying Lin, Chun-Yi Wu, and Jyh-Der Leu.
“A peptide sequence mimicking endogenous cofilin-1 incorporates transmembrane amino acid sequences to enhance cellular uptake of the peptide drug.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 219 changes logged to date.
What changed
The USPTO published patent application US20260108640A1 covering a cofilin-1 peptide sequence designed to enhance cellular uptake in cancer cells. The invention incorporates transmembrane amino acid sequences and can be conjugated with chelators for cancer diagnosis. The application names four inventors and includes CPC classifications A61K 51/08, A61K 45/06, and A61P 35/00.
Pharmaceutical companies and biotechnology firms developing peptide-based oncology therapeutics should monitor this filing as it may affect freedom-to-operate assessments for cofilin-1 targeting approaches. The patent application's scope covers both therapeutic applications affecting cancer cell migration and invasion, as well as diagnostic uses through chelator conjugation.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Peptide Composition for Cancer Approach and Diagnosis
Application US20260108640A1 Kind: A1 Apr 23, 2026
Inventors
Yi-Jang LEE, Min-Ying LIN, Chun-Yi WU, Jyh-Der LEU
Abstract
A peptide sequence mimicking endogenous cofilin-1 incorporates transmembrane amino acid sequences to enhance cellular uptake of the peptide drug. When cofilin peptide drugs are introduced into cancer cells, they affect cancer cell migration and invasion abilities. Furthermore, the peptide sequence can be conjugated with a chelator for cancer diagnosis.
CPC Classifications
A61K 51/08 A61K 45/06 A61P 35/00 A61K 2121/00 A61K 2123/00
Filing Date
2024-10-22
Application No.
18923581
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.